Cutting-edge drug shows promise for patients with NRAS-driven melanoma
Researchers at the Huntsman Cancer Institute have identified a potential new treatment for NRAS-driven melanoma using the drug daraxonrasib. Preclinical trials showed significant tumor shrinkage, offering hope for patients with this aggressive form of skin cancer.
Why it matters
This development addresses a critical unmet need in oncology, as NRAS-driven melanomas have historically been difficult to treat.
edited by Swati Mestri , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in